Global Osteoporosis Drugs Market forecast and analysis (2019-2026), by Drug Class by Route of Administration, by Gender, and by Region.

Global Osteoporosis Market was valued at USD xx million in 2018 and is expected to reach at USD xx million by 2026 at a CAGR of xx% over forecast period 2019-2026. To know about the Research Methodology:-Request Free Sample Report Osteoporosis is a condition in which the bones become weak and fragile due to the loss of tissue. This condition can arise due to hormonal changes, the deficiency of calcium or vitamin.Global Osteoporosis Market is driven by factors such as an increasing geriatric population & post-menopausal women, increasing prevalent cases of osteoporosis in younger population, risk of hip, forearm, and spine fractures, increasing expenditures in R&D for new and innovative drug formulation. However, factors such as the side-effects and adverse reactions by osteoporotic drugs, issues in regulatory approval for drugs and lesser public awareness are restraining the growth of the osteoporosis drugs market.By drug class, the osteoporosis drugs market is segmented into bisphosphonates, parathyroid hormone therapy, selective estrogen receptor modulator (SERM), rank ligand inhibitor, and calcitonin. Among these, the bisphosphonates segment is expected to exhibit highest market share at a CAGR of xx% over forecast period. Whereas, the rank ligand inhibitor drug class category is expected to grow at a highest CAGR over forecast period. By geography Global Osteoporosis Market is segmented into North America, APAC, Europe, MEA & Africa and Latin America. North America is expected to exhibit highest market share at a CAGR of xx% over forecast period. Several collaborative efforts undertaken by major companies to enhance their R&D capabilities and ensure high medical standards are expected to propel the market across this region. Additionally, the majority share can also be attributed to the high disease burden in this region. Moreover, Asia Pacific region is expected to grow at a highest CAGR over forecast period. Key players operating in this market are Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., Ltd., and GlaxoSmithKline plc. Novartis International AG, Merck & Co. Inc., Amgen Inc., and Radius Health Inc. the intensity of rivalry among these players is high. These players are also trying to improve their position in the market and enhancing their regional presence by undergoing mergers and acquisitions, strategic alliances, new product launches, expansion etc. Maximize Market Research, a global market research firm with a dedicated team of specialists and data has carried out extensive research about the Global Osteoporosis Market. The report encompasses the market by different segments and regions, providing an in-depth analysis of the overall industry ecosystem, useful for making an informed strategic decision by the key stakeholders in the industry. Importantly, the report delivers forecasts and share of the market, further giving an insight into the market dynamics and future opportunities that might exist in the Global Osteoporosis Market. The driving forces, as well as considerable restraints, have been explained in depth. In addition to this, competitive landscape describing the strategic growth of the competitors has been taken into consideration for enhancing market know-how of our clients and at the same time explain Global Osteoporosis Market positioning of competitors. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Scope of Global Osteoporosis Market: Inquire before buying

Global Osteoporosis Market Segmentation by Drug Class

• Bisphosphonates • Selective Estrogen Inhibitors Modulator (SERM) • Parathyroid Hormone Therapy • Calcitonin • Rank Ligand Inhibitors • Branded • Generics • Others

Global Osteoporosis Market Segmentation by Gender

• Male • Female

Global Osteoporosis Market Segmentation by Route of Administration

• Oral • Injectable • Others

Global Osteoporosis Market Segmentation by Region

• APAC • North America • Europe • MEA& Africa • Latin America

Global Osteoporosis Drugs Market Major Players

• Eli Lilly and Company • Pfizer Inc. • F. Hoffmann-La Roche • Teva Pharmaceutical Industries Ltd. • GlaxoSmithKline plc. • Novartis International AG • Merck & Co. Inc. • Amgen Inc. • Radius Health Inc.
Global Osteoporosis Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.2. Secondary data 2.3.3. Secondary Sources 2.3.4. Primary Research 2.3.5. Data from Primary Sources 2.3.6. Breakdown of Primary Sources 3. Executive Summary: Global Osteoporosis Drugs Market, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Osteoporosis Drugs Market Analysis and Forecast 6.1. Global Osteoporosis Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Osteoporosis Drugs Market Analysis and Forecast, By Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Osteoporosis Drugs Market Value Share Analysis, By Drug Class 7.4. Global Osteoporosis Drugs Market Size (US$ Mn) Forecast, By Drug Class 7.5. Global Osteoporosis Drugs Market Analysis, By Drug Class 7.6. Global Osteoporosis Drugs Market Attractiveness Analysis, By Drug Class 8. Global Osteoporosis Drugs Market Analysis and Forecast, By Gender 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Osteoporosis Drugs Market Value Share Analysis, By Gender 8.4. Global Osteoporosis Drugs Market Size (US$ Mn) Forecast, By Gender 8.5. Global Osteoporosis Drugs Market Analysis, By Gender 8.6. Global Osteoporosis Drugs Market Attractiveness Analysis, By Gender 9. Global Osteoporosis Drugs Market Analysis and Forecast, by Route of Administration 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Osteoporosis Drugs Market Value Share Analysis, by Route of Administration 9.4. Global Osteoporosis Drugs Market Size (US$ Mn) Forecast, by Route of Administration 9.5. Global Osteoporosis Drugs Market Analysis, by Route of Administration 9.6. Global Osteoporosis Drugs Market Attractiveness Analysis, by Route of Administration 10. Global Osteoporosis Drugs Market Analysis, by Region 10.1. Global Osteoporosis Drugs Market Value Share Analysis, by Region 10.2. Global Osteoporosis Drugs Market Size (US$ Mn) Forecast, by Region 10.3. Global Osteoporosis Drugs Market Attractiveness Analysis, by Region 11. North America Osteoporosis Drugs Market Analysis 11.1. Key Findings 11.2. North America Osteoporosis Drugs Market Overview 11.3. North America Osteoporosis Drugs Market Value Share Analysis, By Drug Class 11.4. North America Osteoporosis Drugs Market Forecast, By Drug ClasS 11.4.1. Bisphosphonates 11.4.2. Selective Estrogen Inhibitors Modulator (SERM) 11.4.3. Parathyroid Hormone Therapy 11.4.4. Calcitonin 11.4.5. Rank Ligand Inhibitors 11.4.6. Branded 11.4.7. Generics 11.4.8. Others 11.5. North America Osteoporosis Drugs Market Value Share Analysis, By Gender 11.6. North America Osteoporosis Drugs Market Forecast, By Gender 11.6.1. Male 11.6.2. Female 11.7. North America Osteoporosis Drugs Market Value Share Analysis, by Route of Administration 11.8. North America Osteoporosis Drugs Market Forecast, by Route of Administration 11.8.1. Oral 11.8.2. Injectable 11.8.3. Others 11.9. North America Osteoporosis Drugs Market Value Share Analysis, by Country 11.10. North America Osteoporosis Drugs Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Osteoporosis Drugs Market Analysis, by Country 11.12. U.S. Osteoporosis Drugs Market Forecast, By Drug Class 11.12.1. Bisphosphonates 11.12.2. Selective Estrogen Inhibitors Modulator (SERM) 11.12.3. Parathyroid Hormone Therapy 11.12.4. Calcitonin 11.12.5. Rank Ligand Inhibitors 11.12.6. Branded 11.12.7. Generics 11.12.8. Others 11.13. U.S. Osteoporosis Drugs Market Forecast, By Gender 11.13.1. Male 11.13.2. Female 11.14. U.S. Osteoporosis Drugs Market Forecast, by Route of Administration 11.14.1. Oral 11.14.2. Injectable 11.14.3. Others 11.15. Canada Osteoporosis Drugs Market Forecast, By Drug Class 11.15.1. Bisphosphonates 11.15.2. Selective Estrogen Inhibitors Modulator (SERM) 11.15.3. Parathyroid Hormone Therapy 11.15.4. Calcitonin 11.15.5. Rank Ligand Inhibitors 11.15.6. Branded 11.15.7. Generics 11.15.8. Others 11.16. Canada Osteoporosis Drugs Market Forecast, By Gender 11.16.1. Male 11.16.2. Female 11.17. Canada Osteoporosis Drugs Market Forecast, by Route of Administration 11.17.1. Oral 11.17.2. Injectable 11.17.3. Others 11.18. North America Osteoporosis Drugs Market Attractiveness Analysis 11.18.1. By Drug Class 11.18.2. By Gender 11.18.3. By Route of Administration 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Development 12. Europe Osteoporosis Drugs Market Analysis 12.1. Key Findings 12.2. Europe Osteoporosis Drugs Market Overview 12.3. Europe Osteoporosis Drugs Market Value Share Analysis, By Drug Class 12.4. Europe Osteoporosis Drugs Market Forecast, By Drug Class 12.4.1. Bisphosphonates 12.4.2. Selective Estrogen Inhibitors Modulator (SERM) 12.4.3. Parathyroid Hormone Therapy 12.4.4. Calcitonin 12.4.5. Rank Ligand Inhibitors 12.4.6. Branded 12.4.7. Generics 12.4.8. Others 12.5. Europe Osteoporosis Drugs Market Value Share Analysis, By Gender 12.6. Europe Osteoporosis Drugs Market Forecast, By Gender 12.6.1. Male 12.6.2. Female 12.7. Europe Osteoporosis Drugs Market Value Share Analysis, by Route of Administration 12.8. Europe Osteoporosis Drugs Market Forecast, by Route of Administration 12.8.1. Oral 12.8.2. Injectable 12.8.3. Others 12.9. Europe Osteoporosis Drugs Market Value Share Analysis, by Country 12.10. Europe Osteoporosis Drugs Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Osteoporosis Drugs Market Analysis, by Country 12.12. Germany Osteoporosis Drugs Market Forecast, By Drug Class 12.12.1. Bisphosphonates 12.12.2. Selective Estrogen Inhibitors Modulator (SERM) 12.12.3. Parathyroid Hormone Therapy 12.12.4. Calcitonin 12.12.5. Rank Ligand Inhibitors 12.12.6. Branded 12.12.7. Generics 12.12.8. Others 12.13. Germany Osteoporosis Drugs Market Forecast, By Gender 12.13.1. Male 12.13.2. Female 12.14. Germany Osteoporosis Drugs Market Forecast, by Route of Administration 12.14.1. Oral 12.14.2. Injectable 12.14.3. Others 12.15. U.K. Osteoporosis Drugs Market Forecast, By Drug Class 12.15.1. Bisphosphonates 12.15.2. Selective Estrogen Inhibitors Modulator (SERM) 12.15.3. Parathyroid Hormone Therapy 12.15.4. Calcitonin 12.15.5. Rank Ligand Inhibitors 12.15.6. Branded 12.15.7. Generics 12.15.8. Others 12.16. U.K. Osteoporosis Drugs Market Forecast, By Gender 12.16.1. Male 12.16.2. Female 12.17. U.K. Osteoporosis Drugs Market Forecast, by Route of Administration 12.17.1. Oral 12.17.2. Injectable 12.17.3. Others 12.18. France Osteoporosis Drugs Market Forecast, By Drug Class 12.18.1. Bisphosphonates 12.18.2. Selective Estrogen Inhibitors Modulator (SERM) 12.18.3. Parathyroid Hormone Therapy 12.18.4. Calcitonin 12.18.5. Rank Ligand Inhibitors 12.18.6. Branded 12.18.7. Generics 12.18.8. Others 12.19. France Osteoporosis Drugs Market Forecast, By Gender 12.19.1. Male 12.19.2. Female 12.20. France Osteoporosis Drugs Market Forecast, by Route of Administration 12.20.1. Oral 12.20.2. Injectable 12.20.3. Others 12.21. Italy Osteoporosis Drugs Market Forecast, By Drug Class 12.21.1. Bisphosphonates 12.21.2. Selective Estrogen Inhibitors Modulator (SERM) 12.21.3. Parathyroid Hormone Therapy 12.21.4. Calcitonin 12.21.5. Rank Ligand Inhibitors 12.21.6. Branded 12.21.7. Generics 12.21.8. Others 12.22. Italy Osteoporosis Drugs Market Forecast, By Gender 12.22.1. Male 12.22.2. Female 12.23. Italy Osteoporosis Drugs Market Forecast, by Route of Administration 12.23.1. Oral 12.23.2. Injectable 12.23.3. Others 12.24. Spain Osteoporosis Drugs Market Forecast, By Drug Class 12.24.1. Bisphosphonates 12.24.2. Selective Estrogen Inhibitors Modulator (SERM) 12.24.3. Parathyroid Hormone Therapy 12.24.4. Calcitonin 12.24.5. Rank Ligand Inhibitors 12.24.6. Branded 12.24.7. Generics 12.24.8. Others 12.25. Spain Osteoporosis Drugs Market Forecast, By Gender 12.25.1. Male 12.25.2. Female 12.26. Spain Osteoporosis Drugs Market Forecast, by Route of Administration 12.26.1. Oral 12.26.2. Injectable 12.26.3. Others 12.27. Rest of Europe Osteoporosis Drugs Market Forecast, By Drug Class 12.27.1. Bisphosphonates 12.27.2. Selective Estrogen Inhibitors Modulator (SERM) 12.27.3. Parathyroid Hormone Therapy 12.27.4. Calcitonin 12.27.5. Rank Ligand Inhibitors 12.27.6. Branded 12.27.7. Generics 12.27.8. Others 12.28. Rest of Europe Osteoporosis Drugs Market Forecast, By Gender 12.28.1. Male 12.28.2. Female 12.29. Rest of Europe Osteoporosis Drugs Market Forecast, by Route of Administration 12.29.1. Oral 12.29.2. Injectable 12.29.3. Others 12.30. Europe Osteoporosis Drugs Market Attractiveness Analysis 12.30.1. By Drug Class 12.30.2. By Gender 12.30.3. By Route of Administration 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Development 13. Asia Pacific Osteoporosis Drugs Market Analysis 13.1. Key Findings 13.2. Asia Pacific Osteoporosis Drugs Market Overview 13.3. Asia Pacific Osteoporosis Drugs Market Value Share Analysis, By Drug Class 13.4. Asia Pacific Osteoporosis Drugs Market Forecast, By Drug Class 13.4.1. Bisphosphonates 13.4.2. Selective Estrogen Inhibitors Modulator (SERM) 13.4.3. Parathyroid Hormone Therapy 13.4.4. Calcitonin 13.4.5. Rank Ligand Inhibitors 13.4.6. Branded 13.4.7. Generics 13.4.8. Others 13.5. Asia Pacific Osteoporosis Drugs Market Value Share Analysis, By Gender 13.6. Asia Pacific Osteoporosis Drugs Market Forecast, By Gender 13.6.1. Male 13.6.2. Female 13.7. Asia Pacific Osteoporosis Drugs Market Value Share Analysis, by Route of Administration 13.8. Asia Pacific Osteoporosis Drugs Market Forecast, by Route of Administration 13.8.1. Oral 13.8.2. Injectable 13.8.3. Others 13.9. Asia Pacific Osteoporosis Drugs Market Value Share Analysis, by Country 13.10. Asia Pacific Osteoporosis Drugs Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Osteoporosis Drugs Market Analysis, by Country 13.12. China Osteoporosis Drugs Market Forecast, By Drug Class 13.12.1. Bisphosphonates 13.12.2. Selective Estrogen Inhibitors Modulator (SERM) 13.12.3. Parathyroid Hormone Therapy 13.12.4. Calcitonin 13.12.5. Rank Ligand Inhibitors 13.12.6. Branded 13.12.7. Generics 13.12.8. Others 13.13. China Osteoporosis Drugs Market Forecast, By Gender 13.13.1. Male 13.13.2. Female 13.14. China Osteoporosis Drugs Market Forecast, by Route of Administration 13.14.1. Oral 13.14.2. Injectable 13.14.3. Others 13.15. India Osteoporosis Drugs Market Forecast, By Drug Class 13.15.1. Bisphosphonates 13.15.2. Selective Estrogen Inhibitors Modulator (SERM) 13.15.3. Parathyroid Hormone Therapy 13.15.4. Calcitonin 13.15.5. Rank Ligand Inhibitors 13.15.6. Branded 13.15.7. Generics 13.15.8. Others 13.16. India Osteoporosis Drugs Market Forecast, By Gender 13.16.1. Male 13.16.2. Female 13.17. India Osteoporosis Drugs Market Forecast, by Route of Administration 13.17.1. Oral 13.17.2. Injectable 13.17.3. Others 13.18. Japan Osteoporosis Drugs Market Forecast, By Drug Class 13.18.1. Bisphosphonates 13.18.2. Selective Estrogen Inhibitors Modulator (SERM) 13.18.3. Parathyroid Hormone Therapy 13.18.4. Calcitonin 13.18.5. Rank Ligand Inhibitors 13.18.6. Branded 13.18.7. Generics 13.18.8. Others 13.19. Japan Osteoporosis Drugs Market Forecast, By Gender 13.19.1. Male 13.19.2. Female 13.20. Japan Osteoporosis Drugs Market Forecast, by Route of Administration 13.20.1. Oral 13.20.2. Injectable 13.20.3. Others 13.21. ASEAN Osteoporosis Drugs Market Forecast, By Drug Class 13.21.1. Bisphosphonates 13.21.2. Selective Estrogen Inhibitors Modulator (SERM) 13.21.3. Parathyroid Hormone Therapy 13.21.4. Calcitonin 13.21.5. Rank Ligand Inhibitors 13.21.6. Branded 13.21.7. Generics 13.21.8. Others 13.22. ASEAN Osteoporosis Drugs Market Forecast, By Gender 13.22.1. Male 13.22.2. Female 13.23. ASEAN Osteoporosis Drugs Market Forecast, by Route of Administration 13.23.1. Oral 13.23.2. Injectable 13.23.3. Others 13.24. Rest of Asia Pacific Osteoporosis Drugs Market Forecast, By Drug Class 13.24.1. Bisphosphonates 13.24.2. Selective Estrogen Inhibitors Modulator (SERM) 13.24.3. Parathyroid Hormone Therapy 13.24.4. Calcitonin 13.24.5. Rank Ligand Inhibitors 13.24.6. Branded 13.24.7. Generics 13.24.8. Others 13.25. Rest of Asia Pacific Osteoporosis Drugs Market Forecast, By Gender 13.25.1. Male 13.25.2. Female 13.26. Rest of Asia Pacific Osteoporosis Drugs Market Forecast, by Route of Administration 13.26.1. Oral 13.26.2. Injectable 13.26.3. Others 13.27. Asia Pacific Osteoporosis Drugs Market Attractiveness Analysis 13.27.1. By Drug Class 13.27.2. By Gender 13.27.3. By Route of Administration 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Development 14. Middle East & Africa Osteoporosis Drugs Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Osteoporosis Drugs Market Overview 14.3. Middle East & Africa Osteoporosis Drugs Market Value Share Analysis, By Drug Class 14.4. Middle East & Africa Osteoporosis Drugs Market Forecast, By Drug Class 14.4.1. Bisphosphonates 14.4.2. Selective Estrogen Inhibitors Modulator (SERM) 14.4.3. Parathyroid Hormone Therapy 14.4.4. Calcitonin 14.4.5. Rank Ligand Inhibitors 14.4.6. Branded 14.4.7. Generics 14.4.8. Others 14.5. Middle East & Africa Osteoporosis Drugs Market Value Share Analysis, By Gender 14.6. Middle East & Africa Osteoporosis Drugs Market Forecast, By Gender 14.6.1. Male 14.6.2. Female 14.7. Middle East & Africa Osteoporosis Drugs Market Value Share Analysis, by Route of Administration 14.8. Middle East & Africa Osteoporosis Drugs Market Forecast, by Route of Administration 14.8.1. Oral 14.8.2. Injectable 14.8.3. Others 14.9. Middle East & Africa Osteoporosis Drugs Market Value Share Analysis, by Country 14.10. Middle East & Africa Osteoporosis Drugs Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Osteoporosis Drugs Market Analysis, by Country 14.12. GCC Osteoporosis Drugs Market Forecast, By Drug Class 14.12.1. Bisphosphonates 14.12.2. Selective Estrogen Inhibitors Modulator (SERM) 14.12.3. Parathyroid Hormone Therapy 14.12.4. Calcitonin 14.12.5. Rank Ligand Inhibitors 14.12.6. Branded 14.12.7. Generics 14.12.8. Others 14.13. GCC Osteoporosis Drugs Market Forecast, By Gender 14.13.1. Male 14.13.2. Female 14.14. GCC Osteoporosis Drugs Market Forecast, by Route of Administration 14.14.1. Oral 14.14.2. Injectable 14.14.3. Others 14.15. South Africa Osteoporosis Drugs Market Forecast, By Drug Class 14.15.1. Bisphosphonates 14.15.2. Selective Estrogen Inhibitors Modulator (SERM) 14.15.3. Parathyroid Hormone Therapy 14.15.4. Calcitonin 14.15.5. Rank Ligand Inhibitors 14.15.6. Branded 14.15.7. Generics 14.15.8. Others 14.16. South Africa Osteoporosis Drugs Market Forecast, By Gender 14.16.1. Male 14.16.2. Female 14.17. South Africa Osteoporosis Drugs Market Forecast, by Route of Administration 14.17.1. Oral 14.17.2. Injectable 14.17.3. Others 14.18. Rest of Middle East & Africa Osteoporosis Drugs Market Forecast, By Drug Class 14.18.1. Bisphosphonates 14.18.2. Selective Estrogen Inhibitors Modulator (SERM) 14.18.3. Parathyroid Hormone Therapy 14.18.4. Calcitonin 14.18.5. Rank Ligand Inhibitors 14.18.6. Branded 14.18.7. Generics 14.18.8. Others 14.19. Rest of Middle East & Africa Osteoporosis Drugs Market Forecast, By Gender 14.19.1. Male 14.19.2. Female 14.20. Rest of Middle East & Africa Osteoporosis Drugs Market Forecast, by Route of Administration 14.20.1. Oral 14.20.2. Injectable 14.20.3. Others 14.21. Middle East & Africa Osteoporosis Drugs Market Attractiveness Analysis 14.21.1. By Drug Class 14.21.2. By Gender 14.21.3. By Route of Administration 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Development 15. South America Osteoporosis Drugs Market Analysis 15.1. Key Findings 15.2. South America Osteoporosis Drugs Market Overview 15.3. South America Osteoporosis Drugs Market Value Share Analysis, By Drug Class 15.4. South America Osteoporosis Drugs Market Forecast, By Drug Class 15.4.1. Bisphosphonates 15.4.2. Selective Estrogen Inhibitors Modulator (SERM) 15.4.3. Parathyroid Hormone Therapy 15.4.4. Calcitonin 15.4.5. Rank Ligand Inhibitors 15.4.6. Branded 15.4.7. Generics 15.4.8. Others 15.5. South America Osteoporosis Drugs Market Value Share Analysis, By Gender 15.6. South America Osteoporosis Drugs Market Forecast, By Gender 15.6.1. Male 15.6.2. Female 15.7. South America Osteoporosis Drugs Market Value Share Analysis, by Route of Administration 15.8. South America Osteoporosis Drugs Market Forecast, by Route of Administration 15.8.1. Oral 15.8.2. Injectable 15.8.3. Others 15.9. South America Osteoporosis Drugs Market Value Share Analysis, by Country 15.10. South America Osteoporosis Drugs Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Osteoporosis Drugs Market Analysis, by Country 15.12. Brazil Osteoporosis Drugs Market Forecast, By Drug Class 15.12.1. Bisphosphonates 15.12.2. Selective Estrogen Inhibitors Modulator (SERM) 15.12.3. Parathyroid Hormone Therapy 15.12.4. Calcitonin 15.12.5. Rank Ligand Inhibitors 15.12.6. Branded 15.12.7. Generics 15.12.8. Others 15.13. Brazil Osteoporosis Drugs Market Forecast, By Gender 15.13.1. Male 15.13.2. Female 15.14. Brazil Osteoporosis Drugs Market Forecast, by Route of Administration 15.14.1. Oral 15.14.2. Injectable 15.14.3. Others 15.15. Mexico Osteoporosis Drugs Market Forecast, By Drug Class 15.15.1. Bisphosphonates 15.15.2. Selective Estrogen Inhibitors Modulator (SERM) 15.15.3. Parathyroid Hormone Therapy 15.15.4. Calcitonin 15.15.5. Rank Ligand Inhibitors 15.15.6. Branded 15.15.7. Generics 15.15.8. Others 15.16. Mexico Osteoporosis Drugs Market Forecast, By Gender 15.16.1. Male 15.16.2. Female 15.17. Mexico Osteoporosis Drugs Market Forecast, by Route of Administration 15.17.1. Oral 15.17.2. Injectable 15.17.3. Others 15.18. Rest of South America Osteoporosis Drugs Market Forecast, By Drug Class 15.18.1. Bisphosphonates 15.18.2. Selective Estrogen Inhibitors Modulator (SERM) 15.18.3. Parathyroid Hormone Therapy 15.18.4. Calcitonin 15.18.5. Rank Ligand Inhibitors 15.18.6. Branded 15.18.7. Generics 15.18.8. Others 15.19. Rest of South America Osteoporosis Drugs Market Forecast, By Gender 15.19.1. Male 15.19.2. Female 15.20. Rest of South America Osteoporosis Drugs Market Forecast, by Route of Administration 15.20.1. Oral 15.20.2. Injectable 15.20.3. Others 15.21. South America Osteoporosis Drugs Market Attractiveness Analysis 15.21.1. By Drug Class 15.21.2. By Gender 15.21.3. By Route of Administration 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Development 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Eli Lilly and Company 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Company Footprint 16.3.2. Pfizer Inc. 16.3.3. F. Hoffmann-La Roche 16.3.4. Teva Pharmaceutical Industries Ltd. 16.3.5. GlaxoSmithKline plc. 16.3.6. Novartis International AG 16.3.7. Merck & Co. Inc. 16.3.8. Amgen Inc. 16.3.9. Radius Health Inc. 17. Primary Key Insights

About This Report

Report ID 39454
Category Healthcare
Published Date Dec 2019
Updated Date Nov 2020
Contact Us